Shattuck Labs (NASDAQ:STTK) is a clinical-stage biotechnology company focused on harnessing the power of commensal bacteria to develop novel therapeutics for chronic inflammatory and other immune-mediated diseases. The company’s proprietary platform engineers naturally occurring microbes to secrete therapeutic proteins directly at disease sites, offering a targeted approach designed to enhance safety and efficacy while minimizing systemic exposure. Shattuck Labs’ platform has been applied to multiple areas, including dermatology and oncology, reflecting the broad potential of microbe-based therapies.
The company’s lead candidate, STK-012, is currently in Phase 1/2 clinical trials for the treatment of moderate-to-severe atopic dermatitis. By leveraging a skin-resident bacterium engineered to produce anti-inflammatory molecules, STK-012 aims to reduce local inflammation and restore healthy barrier function. In addition to dermatology, Shattuck Labs is advancing preclinical programs in oncology and other specialty indications, positioning its platform to address a range of diseases that may benefit from localized biologic delivery.
Founded in 2015 and headquartered in Boulder, Colorado, Shattuck Labs was established on the principle that the human microbiome can be repurposed to treat complex diseases. Since its inception, the company has built a multidisciplinary team of microbiologists, immunologists and drug development experts. Shattuck Labs collaborates with academic centers and biopharmaceutical partners in North America and Europe to support its pipeline and explore new therapeutic applications.
Shattuck Labs is led by CEO Robert “Bob” Rosen, a veteran biopharmaceutical executive with experience commercializing specialty therapeutics. The company’s leadership team and board of directors include industry professionals with backgrounds in cell and gene therapy, clinical development and regulatory affairs. Together, they seek to advance Shattuck’s innovative microbial platform toward regulatory approval and global patient access.
